Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.
No risks detected for CORT from our risk checks.
Share Price & News
How has Corcept Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CORT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: CORT's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: CORT underperformed the US Market which returned 30.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Corcept Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StInvesting in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 268% gain
4 weeks ago | Simply Wall StIs Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shareholder Ownership Skewed Towards Insiders?
Corcept Therapeutics Fundamentals Summary
|CORT fundamental statistics|
Is CORT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CORT income statement (TTM)|
|Cost of Revenue||US$5.12m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.84|
|Net Profit Margin||28.45%|
How did CORT perform over the long term?See historical performance and comparison
Is Corcept Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CORT ($20.43) is trading below our estimate of fair value ($53.95)
Significantly Below Fair Value: CORT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CORT is poor value based on its PE Ratio (24.3x) compared to the US Pharmaceuticals industry average (20.2x).
PE vs Market: CORT is poor value based on its PE Ratio (24.3x) compared to the US market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: CORT is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: CORT is overvalued based on its PB Ratio (4.5x) compared to the US Pharmaceuticals industry average (3x).
How is Corcept Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CORT's forecast earnings growth (28.4% per year) is above the savings rate (2%).
Earnings vs Market: CORT's earnings (28.4% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CORT's revenue (16.2% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: CORT's revenue (16.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CORT's Return on Equity is forecast to be high in 3 years time
How has Corcept Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CORT has high quality earnings.
Growing Profit Margin: CORT's current net profit margins (28.4%) are lower than last year (32.5%).
Past Earnings Growth Analysis
Earnings Trend: CORT's earnings have grown significantly by 23.4% per year over the past 5 years.
Accelerating Growth: CORT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CORT had negative earnings growth (-14.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.5%).
Return on Equity
High ROE: CORT's Return on Equity (18.7%) is considered low.
How is Corcept Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CORT's short term assets ($411.3M) exceed its short term liabilities ($45.4M).
Long Term Liabilities: CORT's short term assets ($411.3M) exceed its long term liabilities ($403.0K).
Debt to Equity History and Analysis
Debt Level: CORT is debt free.
Reducing Debt: CORT has no debt compared to 5 years ago when its debt to equity ratio was 86.6%.
Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.
What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CORT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CORT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CORT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CORT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CORT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joseph Belanoff (64 yo)
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
CEO Compensation Analysis
Compensation vs Market: Joseph's total compensation ($USD5.76M) is above average for companies of similar size in the US market ($USD3.66M).
Compensation vs Earnings: Joseph's compensation has been consistent with company performance over the past year.
Experienced Management: CORT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: CORT's board of directors are seasoned and experienced ( 19.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Corcept Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources
- Name: Corcept Therapeutics Incorporated
- Ticker: CORT
- Exchange: NasdaqCM
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.368b
- Shares outstanding: 115.93m
- Website: https://www.corcept.com
Number of Employees
- Corcept Therapeutics Incorporated
- 149 Commonwealth Drive
- Menlo Park
- United States
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:28|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.